Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report

The definitive efficacy of anaplastic lymphoma kinase (ALK) inhibitors in ALK positive lung squamous cell carcinoma (sqCC) patients remain unclear. Here, we report a case in which brigatinib had a therapeutic effect on ALK‐positive lung squamous cell carcinoma. The patient in this report was diagnos...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shuluan, Zhang, Pei, Wang, Tianyu, Wang, Jie, Duan, Jianchun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636200/
https://www.ncbi.nlm.nih.gov/pubmed/34647426
http://dx.doi.org/10.1111/1759-7714.14133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636200/
https://www.ncbi.nlm.nih.gov/pubmed/34647426
http://dx.doi.org/10.1111/1759-7714.14133

Ejemplares similares